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Abstract
Cytology slides are often unique and irreplaceable. Unlike surgical pathology cases, where
additional paraffin sections can be cut, cytology slides often cannot be duplicated because there are
only a few direct smears or the diagnostic material is present on a single slide. Cytology slides are
often "sent out" to other physicians, laboratories or hospitals, typically so that the pathologist at
the institution where the patient will receive treatment can review the slides. Less often, a cytology
lab sends out the slides for a second opinion or as part of the discovery process in a lawsuit, where
they may or may not be defendants. Rarely, unique and irreplaceable cytology slides are lost. This
article presents a hypothetical scenario that is based on reported state appellate court decisions.
The article discusses some of the legal issues that will affect the defendant cytologist/cytology lab
and the "expert cytologist," and suggests some steps a cytologist/cytology lab can take to minimize
the risk of repercussions from a lost unique and irreplaceable cytology slide.
1. What is already known on this topic?
A WestLaw search (similar to PubMed, but searches state
and federal cases and statutes as well as commentary)
uncovered only a handful of reported appellate cases that
directly applied to the issue of lost cytology slides. There
are many cases and statutes dealing with lost and altered
evidence (other than cytology slides), but the circum-
stances surrounding cytology slides are unique. I did not
see any previous reviews or commentary specifically
addressing the topic. Notwithstanding the relative paucity
of on-point legal authority, the issue is one commonly
addressed by cytology laboratories and cytologists and
many have approached the issue thoughtfully and
prudently.
2. What is not highlighted and what this review 
would answer?
This review synthesizes the available legal cases and
presents to practicing cytologists a short, relatively concise
summary in the format of a hypothetical case. The review
seeks to incorporate the legal issues with the practical
aspects of running a cytology laboratory. The review
answers how some state courts might approach the prob-
lem of lost and irreplaceable cytology slides, and offers
general ideas to cytologist for minimizing the risk from
lost slides.
The big problem of the missing cytology slides
The issues surrounding the decision whether to send out
diagnostic patient slides are more important in cytology
than in surgical pathology because the cytology slides are
typically unique and irreplaceable. Unlike surgical
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pathology cases, where additional paraffin sections can be
cut, cytology slides often cannot be duplicated because
there are only a few direct smears or the diagnostic mate-
rial is present on a single slide.
Slides are routinely "sent out" for a variety of reasons.
Most commonly, slides are sent to another institution
because the patient's pathology slides will be reviewed
before treatment. Some smaller laboratories with only
one or two pathologist may send out slides as part of their
quality assurance procedures. More rarely, but increas-
ingly, slide's are requested as part of existing or contem-
plated litigation. Slides might be lost in any of these
circumstances. A laboratory or hospital might loose the
slides and not discover their absence until the slides are
requested.
This article will discuss the approach the US legal system
takes in addressing what happens when cytology slides are
lost, and what steps a prudent laboratory might take to
manage the risk. The article also intends to improve
cytopathologists' awareness and understanding of some
of the legal issues that arise when evidence is missing and
perhaps promote an international comparative discussion
of alternative legal approaches.
In the US, most of medical malpractice law is made and
interpreted by state legislatures and state courts. What fol-
lows is a hypothetical story based on several legal deci-
sions made by appellate state courts in the United States
and reported in the legal literature. Although based on
real cases and available to the public, the names have been
changed. Importantly, none of this is intended as legal
advice and readers should consult their attorney about
specific questions.
Facts
Rugged Labs (RL) is a small, independent laboratory. Part
of Rugged Labs' work involves providing Big Giant Lab
(BGL) with overflow services for cytopathology. In
December of 1995, BGL bought out RL.
In 1994 and 1995, a RL cytotechnician interpreted two
Pap smears from 30-year-old Ms. Penny as normal. In
1996 a cervical biopsy from Penny showed adenocarci-
noma. Ms. Penny underwent a radical hysterectomy,
which confirmed the invasive endocervical adenocarci-
noma. Ms. Penny is alive today, but endured extended
post-operative hospitalization.
At the time of the hysterectomy, Penny Plaintiff's oncolo-
gist requested that the 1994 and 1995 PAP smear slides be
sent to Dr. Experta, who interpreted both Pap smears as
containing "abnormal cell groups consistent with adeno-
carcinoma." Dr. Experta also reviewed the biopsy and in a
note concluded that the cells on the Pap smears were con-
sistent with the adenocarcinoma diagnosed on the cervi-
cal biopsy.
Approximately 6 months later, Plaintiff Penny decided to
sue for medical malpractice based on failure to diagnose
her endocervical adenocarcinoma on the Pap smears.
At some time before the plaintiff filed her lawsuit Dr.
Experta's assistant apparently mailed the slides back to
BGL. The Pap smear slides are lost, presumably in the
mail, by BGL or Dr. Experta's office.
RL, the independent laboratory, asked the trial court to
grant it summary judgment on the basis that the evidence
was lost and no questions of fact remained. Summary
judgment means that there are no outstanding questions
of fact and the court needs to decide only questions of
law. Summary judgment means there is no trial with a
jury or judge hearing and weighing evidence. The ques-
tion of law RL wanted the court to determine on summary
judgment was that the lost slides substantially prejudiced
RL and summary judgment was, therefore, appropriate.
RL included in its motion for summary judgment an affi-
davit from an expert stating that she could not give an
opinion without having the slides to look at. An affidavit
by Dr. Experta's secretary stated that the slides were
returned to BGL by US mail. BGL submitted an affidavit
attesting they did not lose the slides. The parties to the
lawsuit stipulated that the slides were lost. The trial court
agreed with RL that there should be summary judgment in
RL's favor, reasoning that no questions of fact needed to
be answered and that a trial would unduly prejudice RL
because of the spoliation of evidence. For a summary of
the facts, please see Fig. 1.
The Appellate Court's Opinion
The Plaintiff appealed and the state appellate court
reversed the trial court, concluding that the trial court
made a mistake in not allowing the case to go to trial. The
appeals court reasoned that the case turned on a question
of fact; "The slide either showed the presence of cancer
cells or it did not." The appellate court envisioned the trial
as follows: the cytotechnologist from RL would "testify to
her conclusions" and the plaintiff would have Dr. Experta
testify to her conclusions. There should be a trial because
there were questions of fact including, in the words of the
majority, whether the slide had "cancer cells" or not.
The majority also discounted the affidavit from BGL, stat-
ing that the conclusory statement that BGL had not lost
the slides was not valid; just because BGL couldn't find the
slides did not mean they never had them. In a footnote,
the majority noted that although they aren't accusingCytoJournal 2004, 1:3 http://www.cytojournal.com/content/1/1/3
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anyone, they couldn't help but notice that missing the
slides benefited BGL and RL.
One judge dissented in the three-judge panel that decided
the case. The dissent focused on two points. First, the dis-
sent emphasized that the defendant RL had nothing to do
with loosing the slides. Although the plaintiff, Ms. Penny,
had no "direct role" in the loss of evidence, the dissent
treated Dr. Experta as an agent of the plaintiff and con-
cluded that Dr Experta should have sent the slides back to
RL not GBL. The dissent also reasoned that its approach
would "encourage experts to treat more carefully evidence
delivered into their hands."
Secondly, the dissent emphasized that the defendant RL is
disadvantaged by the loss of the slide and the plaintiff has
gained a significant advantage. The dissent sees a trial
where the cytotechnologist's faces a serious credibility
problem because her testimony will come across as bla-
tantly self-serving. The cytotech will be limited to "opin-
ing that he made no error." Moreover, the fact-finder may
conclude that the cytotechnologist is wrong since many
may presume that the expert pathologist must be right.
Finally, the defendants cannot obtain their own expert to
bolster their case, because no cytology slides remain for
review.
The dissent concludes that summary judgment for RL was
proper because the trial court had good reasons to con-
clude that the lost evidence was going to unduly prejudice
the defendant RL.
Issues
The most obvious issue this case brings up is the difficulty
in deciding what to do when it isn't clear who lost the evi-
dence, or when a third party lost the evidence. In contrast,
is the situation where one party is responsible for inad-
vertently losing the evidence or, even worse, where one
party deliberately loses or destroys evidence. This is called
spoliation of evidence and includes meaningful alteration
of the evidence.
The court will determine the severity of the sanction for
spoliation by the degree of willfulness or bad faith and the
extent of the prejudice suffered by the non-responsible
party. For example, in one case, surgeons performed a
hepatectomy after a small needle core liver biopsy was
interpreted as cancer. The hepatectomy specimen showed
only cirrhosis and no cancer was found. The small needle
liver biopsy was subsequently lost by the hospital. The
patient sued for medical malpractice, claiming that the
core biopsy was misdiagnosed and lead to an unnecessary
hepatectomy. The trial court instructed the jurors that they
could "draw the strongest possible inference against [the
hospital] as to what the lost cytology slides would have
shown." In other words, losing the slide means your
opposition can make the slide show whatever they want.
Interestingly, in the hepatectomy case, the defendants pre-
vailed by arguing that the diagnosis of cancer and the deci-
sion to undergo resection were reasonable, regardless of
the cytology results, because the patient had active hepati-
tis B and a suspicious liver mass on imaging. They argued
that even with a negative cytology result the surgeons
would have gone ahead with the hepatectomy.
But our case is different. Neither party, according to the
majority, is responsible for losing the slides, or put
another way, either party might be responsible for losing
the slides. Several judicial options exist and none are neu-
tral. One is to impose no sanctions and to proceed as
usual, only without the slides, as the majority opinion
advocated. This likely favors the plaintiff, particularly
when there is a subsequent surgical specimen with cancer.
A second option is to try to determine which party the
court thinks is more prejudiced by the lost slides and then
impose a legal remedy, as the trial court did in our hypo-
thetical case by granting summary judgment. The diffi-
culty is that it will not be clear which side is more
prejudiced until the slide is recovered. The critical ques-
tion of whether the negative diagnosis fell below the
standard of care can likely be adequately answered only if
the parties and their experts can review the slide. A third
option might be to not allow Dr. Experta's testimony if the
defendant can show that the expert knew or should have
known that there was going to be litigation [1]. Arguably
Dr. Experta should have returned the slides with greater
care, regardless of whether litigation was contemplated or
whether, as it seems in this case, the slides were sent to
routinely review pathology slides before treatment.
Interestingly, each option leads to a different result based
on bias about which party is ultimately more responsible
or more likely responsible for loosing the slides and a bias
about the standard of care. The majority's opinion
included a note that the benefit to BGL from losing the
slides can't be ignored, a clear statement that the plaintiff
had no responsibility for losing the slides, and a simplistic
view about the standard of care reflected by the statement
that "the slide either showed the cancer cells or it did not."
The majority's subtext is that the plaintiff did nothing
wrong and they weren't completely sure about the labora-
tory. The dissenting opinion, in contrast, treated Dr.
Experta as the plaintiff's agent and was dissatisfied that Dr.
Experta returned the slide to BGL instead of RL, even
though at the time BGL had purchased RL. The dissent
also showed a more nuanced understanding of the stand-
ard of care, conveying skepticism about Dr. Experta's look
back conclusion that the Pap smears were "consistent"
with adenocarcinoma. The dissent reasoned that perhaps
the cells are consistent with malignancy only in theCytoJournal 2004, 1:3 http://www.cytojournal.com/content/1/1/3
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retroscope and that a defense expert might reasonably
conclude that it was "not below the standard of care to
determine the biopsy negative" were the slides available
for review.
Comment
The facts often surrounding a cytopathology medical mal-
practice case are that there is a subsequent biopsy or sur-
gical specimen with a discrepant diagnosis. If, as in the
hypothetical Penny vs. GBL, a court does not dismiss the
plaintiff's case, the absence of the cytology slide will likely
impact the defendant cytologist more adversely because
many people will assume that the cancerous cells were on
the slide and the cytologist or cytotechnologist missed the
cancer, which, after all, was present on the subsequent
biopsy. In the hypothetical's facts, this was particularly
true since Dr. Experta had already opined that the Paps
were "consistent with adenocarcinoma." The defendant
cytologist/cytology lab is at a serious disadvantage if the
court allows Dr. Experta's opinion as admissible evidence.
The majority's comment that GBL benefited from the lost
slides and the appellate court's decision to allow the
plaintiff to go to trial, suggests the court's bias that they
believed Dr Experta's interpretation was the correct one.
Admittedly, a cytology lab or cytologist does benefit if
slides are lost and the court does not attach any responsi-
bility for losing the slides to the potential laboratory or
cytologist defendant, because the plaintiff will not have
enough evidence to prevail. Similarly, if the slides are dis-
carded after the legal time periods the likelihood of a suc-
cessful lawsuit is slim because the plaintiff will not have
enough evidence, and the defendant complied with legal
requirements regarding slide retention. The hypothetical
case of Penny vs GBL differs. Remember that once the
court allows the case to go to trial, GBL only benefits from
absent slides if the defendant initially misinterpreted the
slides. If the slides contained no malignant cells, and Dr.
Experta over-interpreted the slides, then GBL is prejudiced
by not being able to show the slide.
Cytology slides are typically in possession the cytology
labs. The slides may be sent out for a variety of reasons,
but at least initially the lab has possession of the cytology
slides. This is both an advantage and a disadvantage for
the lab. The disadvantage is that if slides are lost while in
the lab's possession a court will typically see it as the lab's
responsibility to safeguard the slides. This allows the
plaintiff to have the jury infer whatever is best for the
plaintiff's case; that the slide had malignant cells when the
cytology diagnosis was benign or that there were only
benign cells when the diagnosis was malignant, as in the
hepatectomy case.
The advantage for the cytology lab is that it is in a position
of relative control. The lab can implement a system to
help reduce the chances of losing a slide and reduce the
risk if a slide is lost. Although the lab may want to employ
the help of an attorney experienced in these matters, there
are several steps every cytology lab can take. First, the lab
should ensure that cytology slides are retained for the time
that the current federal CLIA regulations, applicable state
regulations and the CAP checklist require. All glass cytol-
ogy slides must be retained for at least 5 years and fine
needle aspiration slides retained for 10 years. (Some state
regulations may require longer times.) The CAP checklist
also requires policies for "protecting and preserving the
integrity and retrieval of original slides in cytopathology"
and "to ensure defined handling and documentation of
the use, circulation, referral, transfer and receipt of origi-
nal slides to ensure availability of materials for consulta-
tion and legal proceedings." Keeping careful records about
when and which slides are released to whom is essential
for reducing the risk of losing slides. In the send out cases
where slides are sent out for a routine second opinion not
sought in contemplation of a law suit or because a patient
will be treated elsewhere, the lab might obtain the bor-
rower's explicit written agreement that the borrower has
responsibility for the slides with an explicit provision
about a duty to indemnify the cytology lab for any losses
due to a lost slide or slides. A documented telephone call
to request the return of tardy slides may also be worth-
while. In cases where slides are requested in contempla-
tion of a lawsuit, the lab may be able to implement a
policy that review of slides is done at the lab, ensuring that
the lab retains possession. Alternatively, the lab may pur-
sue or agree to a court order requiring production of the
slides that clearly addresses who is responsible for the
slides and includes an indemnity clause in the event the
slides are lost.
It is reasonable to make a distinction between sending out
non-reproducible slides to an institution that will treat the
patient and sending out non-reproducible slides to the
plaintiff's expert witness. It is, therefore, important that
the lab understands the purpose for which the slides are
requested. A documented telephone conversation may
clarify the purpose of the outside review and allow the lab
to appropriately "triage" the case.
Laboratory administrators should understand that the
cytology lab serves a public function in safeguarding
cytology slides. Court's have recognized a public policy
reason to have the laboratory safeguard slides, in part so
that the slides are available in the event of malpractice lit-
igation. At the same time, many states have statutes that
give patients the right to examine and copy their medical
records (the recent federal HIPAA does the same). These
two propositions are not mutually exclusive. One stateCytoJournal 2004, 1:3 http://www.cytojournal.com/content/1/1/3
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case considered the question of whether a patient/plaintiff
had a right to "immediate possession of pathology slides"
and concluded that the plaintiff did not. The court
decided that the patient's rights did not exceed the
patient's statutory right in the slides. In other words the
court was not going to find a common law, or customary,
right in the slides that gave the patient a greater right than
the applicable statute. The decision noted that the legisla-
tive history of the statute included remarks that pathology
slides were part of the medical record. The judges then
approached the second question about what to do when
the "medical record" cannot be duplicated, as with a Pap
smear or other cytology slide. In answering this question,
the court noted that hospitals and laboratories have pub-
lic as well as private duties. One of their public duties is to
retain slides so that the slides are available in the event of
malpractice litigation. This meant that patients do not
have a legal right to possess parts of the medical record
that cannot be duplicated. The court, however, did not
grant the lab complete authority to never release the
slides. Since the public policy reason depended funda-
mentally on preserving slides to help the legal system run
smoothly, the decision reminded the laboratory or hospi-
tal that, pursuant to the clear terms of a statute, it must
send the original slides to a "licensed institution, labora-
tory or physician" at the patient's written request.
The dissent characterized the pivotal issue differently and
concluded that the patient had a right to immediate pos-
session because the slides contained the patient's cells and
she had the right "to control one's body." The dissent rea-
soned that recent advancement in genetic science and the
accompanying difficult privacy issues raised by genetic
information strengthened the patient's right to possession
of the cells on the glass slide. The majority addressed this
argument and, citing the well known case of Moore vs
Regents of the University of California [2], reminded the
reader that no court has recognized that a patient has
property rights in cells taken for diagnostic purposes. I
mention the dissent to emphasize that the issues sur-
rounding possession and use of glass slides are complex
and evolving and it often difficult to predict what a court
will say.
In summary, lost slides can be a problem for cytology lab-
oratories and cytologists, whether responsible for losing
the slides or not. The prudent cytologist will minimize the
risk of lost slides, because, as the hypothetical case of
Penny v GBL illustrates, lost slides can result in problems
for cytologists and the cytopathology laboratory A good
place to start is to ensure that existing CLIA regulations,
applicable state regulations and other guidelines, such as
the CAP checklist, are in place in the laboratory. Thinking
about the issue and implementing appropriate risk man-
agement strategies with the help of an attorney are also
prudent measures.
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Table 1: The top 10 take home messages
1. Spoliation of evidence includes meaningful alteration of the evidence as well as losing the evidence.
2. A court may look at which party benefits from losing the unique and irreplaceable slides as well as which party was last in possession of the slides 
and impose appropriate sanctions.
3. One remedy a court may impose on the party responsible for losing the slides is to allow the factfinder, whether jury or judge, to infer that the 
slides show whatever is best for the opposition's case.
4. Cytologists should adhere to federal, state and respected published checklists regarding how long to keep slides and implement lab policies 
regarding the circulation and transfer of original slides.
5. A cytology lab should consider calling to find out the reason why a slide is requested so that it can respond appropriately.
6. A cytology laboratory should consider sending unique and irreplaceable cytology slides by registered mail.
7. Some state legislatures and courts recognize a public policy reason for cytology labs to retain and protect cytology slides.
8. Although patients have a right to inspect slides, they typically do not have a legal right to immediate possession.
9. A cytology lab should consider implementing a policy that requires review of the slides at the lab when slide review is in contemplation of a law 
suit. If this is not possible, then the lab can agree to a court order that clearly spells out who is responsible if slides are lost with indemnification to 
the lab for lost slides.
10. When in doubt, the prudent cytologist should contact their attorney.Publish with BioMed Central    and   every 
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